Compare Main Street Capital Corporation (MAIN) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Main Street Capital Corporation vs Summit Therapeutics Inc — how do they compare? Main Street Capital Corporation trades at $54.94 (market cap $5.08B), while Summit Therapeutics Inc trades at $14.41 (market cap $10.48B). The key difference: Summit Therapeutics Inc is far larger — about 2.1× Main Street Capital Corporation's market cap, and Main Street Capital Corporation pays a 8.02% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MAIN | SMMT | |
|---|---|---|
Market Cap | $5.08B | $10.48B |
Sector | Financials | Health |
52-Week High | $67.54 | $29.32 |
52-Week Low | $49.63 | $13.05 |
Dividend Yield | 8.02% | — |
Enterprise Value | — | $9.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Main Street Capital (MAIN) trades at $54.59, down 1.41% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 EPS of $0.93, missing expectations of $1.01, while Q4 2025 beat estimates. Revenue for 2025 was $591.85M with a net income margin of 83.36%, though 2026 projections show a decline to $526M. Analysts maintain a consensus price target of $57.75 with a 'Hold' rating predominance. Recent news highlights MAIN's dividend sustainability amid softening earnings.
MAIN offers a stable dividend yield but faces earnings pressure and revenue decline projections for 2026. The stock's valuation appears reasonable with a P/E of 11.66, yet investor caution is warranted due to mixed earnings performance and potential headwinds from Fed rate cuts impacting BDC earnings. Upside exists if the company meets or exceeds future EPS expectations, supported by its internal management cost advantage.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting ongoing volatility. The company reported a net loss of $1.08 billion for 2025, with negative ROE and ROA, but recent news includes the $105 million divestiture of ridinilazole to sharpen its oncology focus. Technical indicators are bearish, though RSI suggests potential oversold conditions. Analyst consensus remains optimistic with a $15.57 price target and 66.7% buy ratings.
The outlook hinges on clinical success of its lead oncology candidate, ivonescimab, which showed promising survival data. Key risks include high cash burn, binary drug trial outcomes, and shareholder litigation. The stock offers high-risk, high-reward potential for investors betting on pipeline success, but requires careful risk management due to financial losses and volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
